Board of Directors

  • Kevin C. Tang has served as a member of our Board of Directors since February 2009 and as Chairman since July 2012. Mr. Tang is the Managing Director of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Entities managed by Tang Capital Management, LLC hold a significant ownership position in our common stock. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. He currently serves as a director and Chairman of La Jolla Pharmaceutical Company, beginning in August 2014. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from its inception through June 2012 when it was acquired to AstraZeneca PLC. Mr. Tang was previously a director of Penwest Pharmaceuticals Co., beginning in June 2009. He was appointed Chairman in July 2010 and held that role until the Company’s sale to Endo Pharmaceuticals, Inc. September 2010. From 2001 to 2008, he was a director of Trimeris, Inc. which developed and commercialized one of the first major breakthroughs in the treatment of HIV infection. Mr. Tang received a BS degree from Duke University.

  • Barry D. Quart, Pharm.D. has served as a member of our Board of Directors since June 2012 and was appointed as Heron’s Chief Executive Officer in May 2013. In addition, Dr. Quart has served on the Board of Synageva Biopharma Corp. since June 2012. In December 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception until May 2013, and a member of Ardea’s Board until June 2012. Ardea and was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Prior to Ardea, Dr. Quart was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development and the Director of Pfizer’s La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Agouron was acquired by Warner-Lambert for $2.1 billion in 1999. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir), which went from the lab bench to new drug application approval in 38 months. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.

  • Robert H. Rosen has served as a member of our Board of Directors since July 2012. Mr. Rosen was appointed President of the Company in May 2013, after serving as our Senior Vice President and Chief Commercial Officer since October 2012. Additionally, Mr. Rosen currently serves on the Boards of La Jolla Pharmaceutical Company and Conkwest, Inc., since July 2014 and November 2014, respectively. Mr. Rosen served as Managing Partner of Scotia Nordic LLC. From April 2011 to March 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific. During his tenure at Bayer, he led the launch of Nexavar® (sorafanib) for the treatment of renal cell carcinoma and hepatocellular carcinoma. Nexavar’s worldwide sales in 2011 were $1.0 billion. He also led premarket activities for Stivarga® (regorafenib) for gastrointestinal stromal tumors and colon cancer and Alpharadin® (now called Xofigo )(radium 223 dichloride) for prostate cancer. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo, where he was responsible for the development of Sanofi’s U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. Eloxatin U.S. sales in 2005, its third full year on the market, were $1.1 billion, ranking it among the industry’s most successful oncology drug launches. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.

  • Craig A. Johnson has served as a member of our Board of Directors since January 2014. Mr. Johnson is currently a director for Mirati Therapeutics, Inc., and La Jolla Pharmaceutical Company. Mr. Johnson also served as a past director of Ardea Biosciences, Inc. from 2008 until its sale to AstraZeneca PLC in 2012, From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience, Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

  • John W. Poyhonen has served as a member of our Board of Directors since January 2014. Mr. Poyhonen has more than 30 years of diverse experience serving in leadership positions in biotechnology, pharmaceutical and food ingredient companies and commercializing innovative products. Mr. Poyhonen is currently the President, Chief Executive Officer and a director of Senomyx, Inc. He joined Senomyx in 2003 as Vice President and Chief Business Officer; was promoted in 2004 to Vice President and Chief Financial and Business Officer; was named Senior Vice President, Chief Financial and Business Officer in 2006; was promoted to President and Chief Operating Officer in 2009; and promoted to his current role in January 2014. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer, Inc. company, most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts. He was previously a director of Ardea Biosciences, Inc. from 2007 until its acquisition by AstraZeneca PLC for $1.26 billion in June 2012. Mr. Poyhonen received a B.A. degree in marketing from Michigan State University and a M.B.A. degree from the University of Kansas.

  • Christian Waage has served as a director of Heron since June 2016. Mr. Waage has more than 15 years of regulatory, legal, and financial transaction experience primarily in the biotechnology industry. Mr. Waage currently serves as Managing Director at Receptos, a wholly owned subsidiary of Celgene Corporation. Mr. Waage joined Receptos in December 2013 as Senior Vice President and General Counsel and played an instrumental role in its acquisition by Celgene for $7.2B in August 2015. Prior to Receptos, he served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. from July 2012 until its acquisition by Vista Equity Partners for $1B in August 2013. In addition to overseeing its acquisition, his responsibilities at Websense included all legal affairs, including SEC reporting and compliance, corporate governance, litigation and licensing operations. Prior to Websense, Mr. Waage served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. from March 2008 until its acquisition by AstraZeneca PLC for $1.3B in July 2012. Prior to Ardea Biosciences, Mr. Waage practiced law for over a decade at DLA Piper, where he was a partner. Mr. Waage received a J.D. from the University of San Diego School of Law and a B.A. degree in Economics from the University of California, San Diego.

  • Kevin C. Tang has served as a member of our Board of Directors since February 2009 and as Chairman since July 2012. Mr. Tang is the Managing Director of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Entities managed by Tang Capital Management, LLC hold a significant ownership position in our common stock. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. He currently serves as a director and Chairman of La Jolla Pharmaceutical Company, beginning in August 2014. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from its inception through June 2012 when it was acquired to AstraZeneca PLC. Mr. Tang was previously a director of Penwest Pharmaceuticals Co., beginning in June 2009. He was appointed Chairman in July 2010 and held that role until the Company’s sale to Endo Pharmaceuticals, Inc. September 2010. From 2001 to 2008, he was a director of Trimeris, Inc. which developed and commercialized one of the first major breakthroughs in the treatment of HIV infection. Mr. Tang received a BS degree from Duke University.

  • Barry D. Quart, Pharm.D. has served as a member of our Board of Directors since June 2012 and was appointed as Heron’s Chief Executive Officer in May 2013. In addition, Dr. Quart has served on the Board of Synageva Biopharma Corp. since June 2012. In December 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception until May 2013, and a member of Ardea’s Board until June 2012. Ardea and was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Prior to Ardea, Dr. Quart was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development and the Director of Pfizer’s La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Agouron was acquired by Warner-Lambert for $2.1 billion in 1999. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir), which went from the lab bench to new drug application approval in 38 months. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.

  • Robert H. Rosen has served as a member of our Board of Directors since July 2012. Mr. Rosen was appointed President of the Company in May 2013, after serving as our Senior Vice President and Chief Commercial Officer since October 2012. Additionally, Mr. Rosen currently serves on the Boards of La Jolla Pharmaceutical Company and Conkwest, Inc., since July 2014 and November 2014, respectively. Mr. Rosen served as Managing Partner of Scotia Nordic LLC. From April 2011 to March 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific. During his tenure at Bayer, he led the launch of Nexavar® (sorafanib) for the treatment of renal cell carcinoma and hepatocellular carcinoma. Nexavar’s worldwide sales in 2011 were $1.0 billion. He also led premarket activities for Stivarga® (regorafenib) for gastrointestinal stromal tumors and colon cancer and Alpharadin® (now called Xofigo )(radium 223 dichloride) for prostate cancer. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo, where he was responsible for the development of Sanofi’s U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. Eloxatin U.S. sales in 2005, its third full year on the market, were $1.1 billion, ranking it among the industry’s most successful oncology drug launches. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.

  • Craig A. Johnson has served as a member of our Board of Directors since January 2014. Mr. Johnson is currently a director for Mirati Therapeutics, Inc., and La Jolla Pharmaceutical Company. Mr. Johnson also served as a past director of Ardea Biosciences, Inc. from 2008 until its sale to AstraZeneca PLC in 2012, From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience, Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

  • John W. Poyhonen has served as a member of our Board of Directors since January 2014. Mr. Poyhonen has more than 30 years of diverse experience serving in leadership positions in biotechnology, pharmaceutical and food ingredient companies and commercializing innovative products. Mr. Poyhonen is currently the President, Chief Executive Officer and a director of Senomyx, Inc. He joined Senomyx in 2003 as Vice President and Chief Business Officer; was promoted in 2004 to Vice President and Chief Financial and Business Officer; was named Senior Vice President, Chief Financial and Business Officer in 2006; was promoted to President and Chief Operating Officer in 2009; and promoted to his current role in January 2014. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer, Inc. company, most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts. He was previously a director of Ardea Biosciences, Inc. from 2007 until its acquisition by AstraZeneca PLC for $1.26 billion in June 2012. Mr. Poyhonen received a B.A. degree in marketing from Michigan State University and a M.B.A. degree from the University of Kansas.

  • Christian Waage has served as a director of Heron since June 2016. Mr. Waage has more than 15 years of regulatory, legal, and financial transaction experience primarily in the biotechnology industry. Mr. Waage currently serves as Managing Director at Receptos, a wholly owned subsidiary of Celgene Corporation. Mr. Waage joined Receptos in December 2013 as Senior Vice President and General Counsel and played an instrumental role in its acquisition by Celgene for $7.2B in August 2015. Prior to Receptos, he served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. from July 2012 until its acquisition by Vista Equity Partners for $1B in August 2013. In addition to overseeing its acquisition, his responsibilities at Websense included all legal affairs, including SEC reporting and compliance, corporate governance, litigation and licensing operations. Prior to Websense, Mr. Waage served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. from March 2008 until its acquisition by AstraZeneca PLC for $1.3B in July 2012. Prior to Ardea Biosciences, Mr. Waage practiced law for over a decade at DLA Piper, where he was a partner. Mr. Waage received a J.D. from the University of San Diego School of Law and a B.A. degree in Economics from the University of California, San Diego.